A Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of TERN-601 in Adults With Overweight or Obesity

Description

This is a Phase 2a multicenter, randomized, double-blind, placebo-controlled clinical trial studying the efficacy, safety, and tolerability of orally administered TERN-601 in adults with overweight or obesity.

Conditions

Overweight or Obesity

Talk to us

Study Overview

On this page

Study Details

Study overview

This is a Phase 2a multicenter, randomized, double-blind, placebo-controlled clinical trial studying the efficacy, safety, and tolerability of orally administered TERN-601 in adults with overweight or obesity.

A Phase 2 Study to Evaluate the Efficacy, Safety, and Tolerability of TERN-601 in Adults With Overweight or Obesity

A Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of TERN-601 in Adults With Overweight or Obesity

Condition
Overweight or Obesity
Intervention / Treatment

-

Contacts and Locations

Birmingham

FALCON Research Site, Birmingham, Alabama, United States, 35233

Homewood

FALCON Research Site, Homewood, Alabama, United States, 35209

Tucson

FALCON Research Site, Tucson, Arizona, United States, 85712

Spring Valley

FALCON Research Site, Spring Valley, California, United States, 91978

Port Orange

FALCON Research Site, Port Orange, Florida, United States, 32127

Louisville

FALCON Research Site, Louisville, Kentucky, United States, 40213

Marrero

FALCON Research Site, Marrero, Louisiana, United States, 70072

Boston

FALCON Research Site, Boston, Massachusetts, United States, 02114

Rochester

FALCON Research Site, Rochester, Minnesota, United States, 55905

Saint Peters

FALCON Research Site, Saint Peters, Missouri, United States, 63303

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. Female or male aged 18 to 75 years
  • 2. Body mass index (BMI) of:
  • 1. ≥ 30 kg/m\^2 to \< 50 kg/m\^2
  • 2. ≥ 27 kg/m\^2 to \< 30 kg/m\^2 with at least 1 weight-related comorbidity
  • 3. HbA1c \< 6.5%
  • 4. Stable self-reported body weight for at least 3 months prior to study (\< 5% body weight gain or loss)
  • 1. Have diabetes mellitus
  • 2. Have obesity induced by medication or other diagnosed endocrinologic disorders
  • 3. Have had or are planning surgical treatment or device-based therapy for obesity
  • 4. Lifetime history of suicide attempt

Ages Eligible for Study

18 Years to 75 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Terns, Inc.,

Study Record Dates

2026-12